ARCHIVES

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Community ASSN. Developing Clinical Standards Catalogue; Perry Leaves NCI For NIH Position

November 15, 1974

New Report On Survival Data Available From NCI

July 25, 1975

NIH Responds To IOM Report On Women’s Health Initiative

November 12, 1993

DCE Advisors OK RFAs In Occupational Cancer, H. Pylori

April 1, 1994

Includes 8-page April 2002 Business & Regulatory Report.

May 3, 2002

FDA Grants Approvals to Lynparza, Blincyto, Xgeva, Gardasil 9 and Cyramza

December 26, 2014